Relapsed Refractory Multiple Myeloma (RRMM)Phase 1MAGENTANCT07032714

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

A Phase 1 study testing Talquetamab, Mezigdomide and Dexamethasone in people with Relapsed Refractory Multiple Myeloma (RRMM), run by Massachusetts General Hospital at 3 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Relapsed Refractory Multiple Myeloma (RRMM)
What is being tested?: Talquetamab, Mezigdomide and Dexamethasone
Type of treatment: Pill or oral medicine, Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 25 participants
Where: 3 sitesUnited States
Study dates: 19 Dec 2025to 1 Jul 2028
Phase: Phase 1
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to their future medical care.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix).
Age ≥ 18 years
Measurable disease of multiple myeloma as defined by at least one of the following:
Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval
≥ 200 mg of monoclonal protein in the urine on 24-hour urine protein electrophoresis

Show all 23Show fewer

Serum free light chain (FLC) ≥ 100 mg/L (10 mg/dL) and abnormal serum free light chain ratio
Previously treated relapsed and refractory multiple myeloma:
Patients must have received at least three prior lines of therapy;
Prior therapy including an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody (either in separate regimens or within the same regimen); and
Disease progression on, or within 60 days of completion of last therapy.
ANC ≥ 1000/μL. G-CSF is not permitted within 14 days of screening.
Platelet count ≥ 50,000/µL. Platelet transfusion and thrombopoietin receptor agonists are not permitted within 7 days of screening.
Hemoglobin ≥ 8 g/dL. Red blood cell transfusions are permitted to meet eligibility criteria.
Calculated creatinine clearance of ≥ 30 mL/min by Modified Diet in Renal Disease (MDRD) formula or Cockcroft-Gault formula
Serum bilirubin values < 1.5 x ULN. Isolated bilirubin x 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%. Patients with elevated bilirubin due to Gilbert's syndrome may be permitted with PI approval (e.g. total bilirubin <3 mg/dL and normal direct bilirubin); and
Serum aspartate transaminase (ALT) and aspartate transaminase (AST) values < 2.5 × the upper limit of normal (ULN) of the institutional laboratory reference range.
Must be able to comply with thromboembolism prophylaxis with e.g. acetylsalicylic acid (ASA), apixaban, rivaroxaban, lower molecular weight heparin, or equivalent.
Females of childbearing potential (FCBP) must:
Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. The subject must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact.
Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with two reliable forms of contraception as defined by the Pregnancy Prevention Plan.
Male subjects must follow the mezigdomide Pregnancy Prevention Plan (see Appendix).
Agree to follow the lifestyle considerations in Section 3.4 regarding blood donation, hospitalization and being in proximity to the hospital, and driving or operating heavy machinery.

Who cannot join

Participants who have had myeloma therapy or investigational drug within 2 weeks prior to start of treatment or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
Participants who are receiving any investigational agents.
Prior therapy with mezigdomide or iberdomide.
Prior therapy with anti-GPRC5D therapy (e.g. talquetamab).
Prior therapy with bispecific antibody therapy within three months
Prior therapy with gene-modified adoptive cell therapy (e.g. CAR T-cells, NK cells) within three months

Show all 9Show fewer

Plasmapheresis within seven days prior to start of study treatment.
Primary refractory disease.
Concomitant high dose corticosteroids. Low dose corticosteroids (maximum dose prednisone 10 mg/day or equivalent) are permitted if given for disorders other than myeloma, e.g. adrenal insufficiency, rheumatoid arthritis, etc.

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Andrew J. Yee, MD contact

617-724-4000

ayee1@mgh.harvard.edu

United States3 sites, 3 recruiting

Massachusetts General Hospital
Boston, Massachusetts, 02114
Andrew J. Yee, MD, 617-724-4000, ayee1@mgh.harvard.edu
Andrew J. Yee, MD
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115
Jessica Leigel, MD, 617-667-9920, jliegel@bidmc.harvard.edu
Jessica Liegel, MD
Not yet recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Shonali Midha, MD, 617-632-3823, shonali_midha@dfci.harvard.edu
Shonali Midha, MD
Not yet recruiting

Other trials in United States

About this study

Official title: MAGENTA: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Read the detailed description

This phase 1 open-label study will determine the recommended dose and schedule of mezigdomide and talquetamab in triple class exposed relapsed and refractory multiple myeloma. This study aims to enroll 25 participants including Cohorts A and B, and will follow a dose escalation schedule. Treatment is until progression or withdrawal of consent. The U.S. Food and Drug Administration (FDA) has not approved the combination of drugs mezigdomide, talquetamab, and dexamethasone as treatment for any disease. The FDA has not approved mezigdomide as a treatment for any disease. The FDA has approved talquetamab for the treatment of relapsed refractory multiple myeloma in patients who have already received 4 prior lines of therapy. Dexamethasone is approved by the FDA to treat multiple diseases including multiple myeloma.

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Being tested: Talquetamab, Mezigdomide, Dexamethasone
Keywords: Relapsed Refractory Multiple Myeloma (RRMM), Prior therapy, Triple class exposed RRMM
Medical subject headings: Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

TalquetamabDrug
Talquetamab is injected under the skin (subcutaneously injected) by trained medical staff. During first cycle of talquetamab, the dose of talquetamab will increase until the goal dose (treatment dose) is reached (pre-determined dose escalation).
MezigdomideDrug
Administered orally once per day (days 1-21 of applicable 28-day cycles; Days 1-7 of the 7-day Cohort B pre-phase cycle).
DexamethasoneDrug
Administered orally once per day, at the schedule outlined in the Arm Descriptions.

Study groups in NCT07032714
Study group	Role	What they receive
Cohort A	Experimental	Cycle 1: Talquetamab and dexamethasone at a pre-determined escalating dose of talquetamab. Talquetamab is subcutaneously injected on Day 1, 4, 8, and 15 of the 28-day cycle. Dexamethasone is administered orally before receiving talquetamab (Days 1, 4, 8, 15). Cycle 2+: Mezigdomide, talquetamab, and dexamethasone Talquetamab is administered on Day 1 and 15 of cycles 2-6 and on Day 1 of cycles 7-12. Mezigdomide is administered orally once per day on days 1-21 of each 28-day cycle starting with cycle 2. This can continue until disease progression or withdrawal. Dexamethasone is administered orally once per week starting on Day 1 of Cycle 2 through cycle 6; the weekly dose will be split into 2 days. Receives: Drug: Talquetamab; Drug: Mezigdomide; Drug: Dexamethasone
Cohort B	Experimental	Cohort B takes place after Cohort A. Pre-phase 7 day cycle: Mezigdomide is administered orally once per day on Days 1-7. Dexamethasone is administered orally on Days 1 and 2. Cycle 1 (28 day cycle): Talquetamab is subcutaneously injected on Day 1, 4, 8, and 15 at a pre-determined escalating dose. Mezigdomide is given orally on days 1-14. Dexamethasone is administered orally as pre-medications before receiving talquetamab. Cycle 2+ (28 day cycle): Talquetamab on Days 1 and 15 of cycles 2-6; then Day 1 of cycles 7-12. Mezigdomide on Days 1-21 of cycles 2+ until disease progression or withdrawal. Dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, 23 of cycles 2-6. Receives: Drug: Talquetamab; Drug: Mezigdomide; Drug: Dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

Recommended Dose
To determine the recommended dose and schedule of mezigdomide and talquetamab in triple class exposed, relapsed and refractory multiple myeloma (RRMM), the dose level where 2 of 6 participants experience a DLT is considered the maximum tolerated dose. The dose level below this will be considered a recommended phase 2 dose. Or if dose level 2 is reached (mezigdomide 1 mg po for 21 out of 28 days) and there are ≤1 DLTs out of 6 participants, then dose level 2 will be considered the recommended phase 2 dose. Data from the secondary outcomes (frequency of adverse events, serious adverse events, and dose-limiting toxicities) will be used for this outcome.
Measured: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)

Secondary outcomes (6)

Frequency of adverse events
Assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, the frequency of AEs will be tabulated by cohort and dose.
Measured: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
Frequency of serious adverse events
Assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, the frequency of serious AEs will be tabulated by cohort and dose.
Measured: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
Frequency of dose-limiting toxicities (DLT)
Unacceptable toxicity will be defined as grade 3-4 CRS, grade 3-4 ICANS, and grade 4, treatment-related, non-hematologic adverse events. Assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 when applicable. The frequency and type of DLTs will be tabulated by cohort and dose.
Measured: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
Overall response rate (ORR)
Response rate will be according to IMWG criteria. Overall response rate is rate of patients achieving partial response or better.
Measured: Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal)
Progression Free Survival (PFS)
Progression-free survival (PFS) is defined as the time from start of treatment to disease progression or death from any cause. Patients who have not progressed or died are censored at the date last known progression-free. Response will be according to IMWG criteria. PFS will be determined from first dose of study drug, according to Kaplan-Meier methodology.
Measured: Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal)
Overall Survival (OS)
Overall survival (OS) is defined as the time from start of treatment to death due to any cause or censored at date last known alive. Response will be according to IMWG criteria. OS will be determined from first dose of study drug, according to Kaplan-Meier methodology.
Measured: Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

19 Dec 20251 Jul 2028

First posted24 Jun 2025
Study start19 Dec 2025
Primary completion1 Jul 2027 (estimated)
Study completion1 Jul 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Relapsed Refractory Multiple Myeloma (RRMM)Studies of the same condition, open and under way.
More trials run by Massachusetts General HospitalThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Sequential
Masking: None (open label)
Enrolment: 25 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07032714
Sponsor's protocol ID: 25-320
Acronym: MAGENTA
Status last verified: Feb 2026
First submitted: 16 Jun 2025
Last updated: 13 Apr 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Andrew J. Yee, MD, ayee1@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Study at a glance

From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: MAGENTA: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT07032714
Acronym / sponsor ID: MAGENTA / 25-320
Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Keywords: Relapsed Refractory Multiple Myeloma (RRMM), Prior therapy, Triple class exposed RRMM
Phase: Phase 1
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 25 participants (estimated)
Lead sponsor: Massachusetts General HospitalUniversity, hospital or other
Collaborators: Celgene Corporation, Janssen Research & Development, LLC
Study start: 19 Dec 2025 (actual)
Primary completion: 1 Jul 2027 (estimated)
Study completion: 1 Jul 2028 (estimated)
First posted: 24 Jun 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Sequential
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Cohort A	Experimental	Drug: Talquetamab, Drug: Mezigdomide, Drug: DexamethasoneCycle 1: Talquetamab and dexamethasone at a pre-determined escalating dose of talquetamab. Talquetamab is subcutaneously injected on Day 1, 4, 8, and 15 of the 28-day cycle. Dexamethasone is administered orally before receiving talquetamab (Days 1, 4, 8, 15). Cycle 2+: Mezigdomide, talquetamab, and dexamethasone Talquetamab is administered on Day 1 and 15 of cycles 2-6 and on Day 1 of cycles 7-12. Mezigdomide is administered orally once per day on days 1-21 of each 28-day cycle starting with cycle 2. This can continue until disease progression or withdrawal. Dexamethasone is administered orally once per week starting on Day 1 of Cycle 2 through cycle 6; the weekly dose will be split into 2 days.
Cohort B	Experimental	Drug: Talquetamab, Drug: Mezigdomide, Drug: DexamethasoneCohort B takes place after Cohort A. Pre-phase 7 day cycle: Mezigdomide is administered orally once per day on Days 1-7. Dexamethasone is administered orally on Days 1 and 2. Cycle 1 (28 day cycle): Talquetamab is subcutaneously injected on Day 1, 4, 8, and 15 at a pre-determined escalating dose. Mezigdomide is given orally on days 1-14. Dexamethasone is administered orally as pre-medications before receiving talquetamab. Cycle 2+ (28 day cycle): Talquetamab on Days 1 and 15 of cycles 2-6; then Day 1 of cycles 7-12. Mezigdomide on Days 1-21 of cycles 2+ until disease progression or withdrawal. Dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, 23 of cycles 2-6.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (23 listed)

Participant has given voluntary signed written informed consent before performance of any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to their future medical care.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix).
Age ≥ 18 years
Measurable disease of multiple myeloma as defined by at least one of the following:
Previously treated relapsed and refractory multiple myeloma:

Key exclusion criteria (9 listed)

Participants who have had myeloma therapy or investigational drug within 2 weeks prior to start of treatment or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
Participants who are receiving any investigational agents.
Prior therapy with mezigdomide or iberdomide.
Prior therapy with anti-GPRC5D therapy (e.g. talquetamab).
Prior therapy with bispecific antibody therapy within three months

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
TalquetamabTalquetamab is injected under the skin (subcutaneously injected) by trained medical staff. During first cycle of talquetamab, the dose of talquetamab will increase until the goal dose (treatment dose) is reached (pre-determined dose escalation).	Drug	Cohort A, Cohort B
MezigdomideAdministered orally once per day (days 1-21 of applicable 28-day cycles; Days 1-7 of the 7-day Cohort B pre-phase cycle).	Drug	Cohort A, Cohort B
DexamethasoneAdministered orally once per day, at the schedule outlined in the Arm Descriptions.	Drug	Cohort A, Cohort B

Primary outcome

Recommended Dose
Time frame: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
To determine the recommended dose and schedule of mezigdomide and talquetamab in triple class exposed, relapsed and refractory multiple myeloma (RRMM), the dose level where 2 of 6 participants experience a DLT is considered the maximum tolerated dose. The dose level below this will be considered a recommended phase 2 dose. Or if dose level 2 is reached (mezigdomide 1 mg po for 21 out of 28 days) and there are ≤1 DLTs out of 6 participants, then dose level 2 will be considered the recommended phase 2 dose. Data from the secondary outcomes (frequency of adverse events, serious adverse events, and dose-limiting toxicities) will be used for this outcome.

6 secondary outcomes

Frequency of adverse events
Time frame: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
Frequency of serious adverse events
Time frame: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
Frequency of dose-limiting toxicities (DLT)
Time frame: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)
Overall response rate (ORR)
Time frame: Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal)
Progression Free Survival (PFS)
Time frame: Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal)
Overall Survival (OS)
Time frame: Day 1 of treatment through 2 years post last-dose (estimated total time to be 3 years; treatment is until disease progression or withdrawal)

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
Individual participant dataSharing planned: Yes. The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Andrew J. Yee, MD, ayee1@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Related trials for Relapsed Refractory Multiple Myeloma (RRMM)

Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
RecruitingPhase 1/2
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
RecruitingPhase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Multiple Myeloma
RecruitingPhase 3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Relapsed and/or Refractory Multiple Myeloma (RRMM)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Andrew J. Yee, MD contact

617-724-4000

ayee1@mgh.harvard.edu

Andrew J. Yee, MD principal investigator

Massachusetts General Hospital

3 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Talquetamab, Mezigdomide and Dexamethasone in people with Relapsed Refractory Multiple Myeloma (RRMM), run by Massachusetts General Hospital at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Andrew J. Yee, MD (617-724-4000, ayee1@mgh.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recommended Dose (time frame: Day 1 of treatment through 30 days post last-dose (treatment is until disease progression or withdrawal; estimated to be 1 year from Day 1 of treatment)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07032714.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.